Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae
Open Access
- 20 March 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 57 (5) , 937-944
Abstract
Objectives: To apply clarithromycin as an immunomodulatory treatment in experimental infection caused by pan-resistant Klebsiella pneumoniae. Methods: Acute pyelonephritis was induced in 80 rabbits after inoculation of the test isolate in the renal pelvis. Rabbits were divided into eight groups, with 10 animals in each group. In groups A–D, therapy was administered simultaneously with bacterial challenge as follows: A, controls; B, intravenous clarithromycin; C, amikacin; and D, both agents. In groups E–H, therapy was administered 24 h after bacterial challenge as follows: E, controls; F, intravenous clarithromycin; G, amikacin; and H, both agents. Blood was sampled for estimation of tumour necrosis factor-α (TNF-α) and malondialdehyde (MDA); monocytes were isolated for determination of intracellular activity of caspase-3 and ex vivo TNF-α secretion. Four days after bacterial challenge, animals were sacrificed for quantitative cultures and biopsies of organs. Results: Serum TNF-α at 48 h was lower in groups B, C and D compared with group A. Activity of caspase-3 of monocytes was lower at 48 h in group D compared with group A. Bacterial loads of liver and spleen were decreased in group D compared with those of group A. The numbers of inflammatory cells of spleen of group B were lower compared with those of group A; those of kidney and mesenteric lymph nodes of group D were lower than those of group A. Serum MDA of group H was lower than that of group E and serum TNF-α of group F was lower compared with that of group E. TNF-α of monocyte supernatants and activity of caspase-3 of monocytes of group F were lower than those of group E. Bacterial tissue loads did not differ among groups E, F, G and H. The numbers of inflammatory cells of liver of groups F and H were lower compared with those of group E; those of kidney of groups F, G and H were lower compared with those of group E. Conclusions: Clarithromycin administered intravenously in experimental infection caused by pan-resistant K. pneumoniae attenuated systemic inflammatory response and local tissue damage. This effect is probably attributed to immunomodulatory intervention on blood monocytes.Keywords
This publication has 17 references indexed in Scilit:
- Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coliInternational Journal of Antimicrobial Agents, 2005
- Clarithromycin: Immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coliScandinavian Journal of Infectious Diseases, 2005
- Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosisJournal of Antimicrobial Chemotherapy, 2004
- Immunomodulatory Clarithromycin Treatment of Experimental Sepsis and Acute Pyelonephritis Caused by Multidrug-Resistant Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2004
- Rapid, fluorimetric–liquid chromatographic determination of malondialdehyde in biological samplesJournal of Chromatography B, 2002
- Nosocomial Bacteremia Caused by Antibiotic‐Resistant Gram‐Negative Bacteria in Critically Ill Patients: Clinical Outcome and Length of HospitalizationClinical Infectious Diseases, 2002
- Clinical Trials of Immunomodulatory Therapies in Severe Sepsis and Septic ShockClinical Infectious Diseases, 2002
- In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis modelJournal of Antimicrobial Chemotherapy, 2001
- Serotype‐Related Differences in Inflammatory Response toStreptococcus pneumoniaein Experimental MeningitisThe Journal of Infectious Diseases, 1997
- Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complexAntimicrobial Agents and Chemotherapy, 1994